The consolidated revenue from operations of the company stood at Rs 1,314.33 crore for the quarter under consideration. It was Rs 1,209.13 crore for the same period a year ago, it added.
“It was another good quarter for the company led by strong growth in the India formulation business. The API Business continued to perform well in the current quarter,” Alembic Pharmaceuticals Managing Director Pranav Amin said.
Shares of Alembic Pharmaceuticals were trading at Rs 1,055.20 per scrip on the BSE, down 1.39 per cent from its previous close.